New Study Identifies Challenges for COVID-19 Vaccine Adoption

▴ New Study Identifies Challenges for COVID-19 Vaccine Adoption
Advisory firm Avenue Group® conducted a series of one-on-one, in-depth phone interviews with doctors, nurses, and members of the general public to better understand what needs to happen in order for Americans to feel comfortable choosing to take a COVID-19 vaccine.

Advisory firm Avenue Group® conducted a series of one-on-one, in-depth phone interviews with doctors, nurses, and members of the general public to better understand what needs to happen in order for Americans to feel comfortable choosing to take a COVID-19 vaccine.

The World Health Organization estimates that 65 to 75 percent of the population well over 200 million Americans need to have antibodies either by means of a vaccine or through recovery from the virus to reach herd immunity. Last month, Dr. Anthony Fauci said, "We know what the efficacy of the vaccines is, but its effectiveness will depend on how many people take the vaccine."

Avenue Group's research identified several areas that need to be addressed to increase the vaccination adoption rate. Avenue Group Founder Jeremy Greenberg said, "Only half of the participants told us that they are likely to take a COVID-19 vaccine. Vaccine safety and side effects are viewed as the most important factors driving the vaccination decision. Two-thirds of those not likely to take the vaccine doubt the safety of it. These are concerning issues that need to be addressed by policy leaders and health experts."

Several concerning themes emerged from Avenue Group's interviews: women are more often the gatekeepers for households and are less likely to take a COVID-19 vaccine than men, over one-third of doctors and nurses are not yet supportive of taking a vaccine, and some do not consider their doctor's recommendation important and are leery of new vaccines.

There were encouraging themes as well. President-elect Joe Biden's victory had a net positive impact on vaccination adoption. Half of Biden voters said that Biden's forthcoming oversight of distribution makes them more likely to take it, while Trump voters said that their vaccine decision is unaffected by who is president. Older and high-risk participants were more likely to take the vaccine. A 74-year-old retired participant from Port St. Lucie, Florida, said, "It makes sense for me. I'm older and I have a low immune system."

About the Study:

Avenue Group conducted confidential one-on-one interviews over the phone between November 13-23, 2020, during a surge in coronavirus cases across the U.S., and, after President-elect Joe Biden had been declared the winner of the presidential election. The average interview length was 30 minutes. The 40 participants in the study included 17 individuals from the medical community (11 doctors, six nurses) and 23 members of the general public.

The findings from this small study should be considered directional as this was not a large population study, and we prioritized deeper, live interactions over sample size. Participants constituted a diverse representation of American society, across gender, race, income, geography, employment status, level of education, political affiliation, and other demographic factors.

About Avenue Group: Avenue Group® advises private equity firms, Fortune 500s, mid-market companies, and non-profits. The company combines data with a firsthand narrative to drive smarter decisions with a primary research-first approach. Avenue Group sources conduct and analyze in-depth interviews and surveys to develop meaningful actionable insights for clients. The firm generates real-time market feedback to move beyond existing data and industry stereotypes.

Tags : #NewYork #America #AvenueGroup #WHO #Covid19 #Covid19VAccine #DrAnthonyFauci #FightAgainstVirus #Vaccination

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

If some countries in Asia Pacific can be on track to end AIDS then why cannot all?July 26, 2024
Karan Johar and Guneet Monga Kapoor’s 'Gyaarah Gyaarah' trailer breaks time barriers on ZEE5July 26, 2024
If some countries in Asia Pacific can be on track to end AIDS then why cannot all?July 26, 2024
Investing in India’s Path to a Healthier and Brighter FutureJuly 26, 2024
Your Medication Could Be Useless This Summer: How Heat Waves Affect Drug SafetyJuly 26, 2024
Innovative Approach to Adolescent Weight Loss: Combining Meal-Replacement Therapy with Financial IncentivesJuly 26, 2024
Promoting School Cardiopulmonary Resuscitation (CPR) Program in India: A Step Towards Saving LivesJuly 26, 2024
Education Budget 2024: A Step Towards Better Learning : Gargi Limaye July 25, 2024
AI assistant shows great promise in cataract care pathwayJuly 25, 2024
Publishing Powerhouse Devangini : A Force of Resilience and Empowerment in LiteratureJuly 25, 2024
Alarm rings in Asia Pacific for not making U-equals-U and HIV prevention accessible to allJuly 25, 2024
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular DiseasesJuly 24, 2024
Nurturing Souls revolutionises 1000 Child-Parent Relationships for Better Career Choices & improved Mental HealthJuly 24, 2024
How to Improve Sleep Quality in Adolescents: Insights from a New StudyJuly 24, 2024
Tragic Nipah Virus Death of 14-Year-Old in Kerala: What You Need to KnowJuly 24, 2024
India Inaugurates First Overseas Jan Aushadi Kendra in MauritiusJuly 24, 2024
Budget Reaction Quote - Ms. Deepshikha Sharma, CEO, Sharp Sight Eye HospitalsJuly 23, 2024
Quote to be attributed to Mr. Jatinder Paul Singh, CEO & Co - Founder of Viacation Tourism:July 23, 2024
Budget Reaction by Anjan Bose, Founding Secretary General, NATHEALTH July 23, 2024
Mr. Niranjan Kirloskar, Managing Director, Fleetguard Filters Private Limited- BUDGET REACTIONJuly 23, 2024